Impact of 1p/19q codeletion on the diagnosis and prognosis of different grades of meningioma

References

• Riemenschneider MJ, Perry A, Reifenberger G. Histological classification and molecular genetics of meningiomas. Lancet Neurol 2006;5:1045–54.
   PubMed Web of Science ®Google Scholar
• Lantos PL, Vandenberg S, Kleihues P. Tumours of the nervous system. Greenfield’s Neuropathol 2002;2:767–1052.
   Google Scholar
• Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97–109.
   PubMed Web of Science ®Google Scholar
• Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM. Epidemiology of intracranial meningioma. Neurosurgery 2005;57:1088–95.
   PubMed Web of Science ®Google Scholar
• Jenkinson MD, Weber DC, Haylock BJ, Mallucci CL, Zakaria R, Javadpour M. Atypical meningoma: current management dilemmas and prospective clinical trials. J Neurooncol 2015;121:1–7.
   PubMed Web of Science ®Google Scholar
• Sulman EP, Dumanski JP, White PS, et al. Identification of a consistent region of allelic loss on 1p32 in meningiomas: correlation with increased morbidity. Cancer Res 1998;58:3226–30.
   PubMed Web of Science ®Google Scholar
• Choy W, Kim W, Nagasawa D, et al. The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. Neurosurg Focus 2011;30:E6.
   PubMed Web of Science ®Google Scholar
• Zang KD. Cytological and cytogenetical studies on human meningioma. Cancer Genet Cytogenet 1982;6:249–74.
   PubMed Web of Science ®Google Scholar
• Perry A, Louis D, Scheithauer B, et al. Meningiomas. WHO classification of tumors of the central nervous system. Lyon: IARCC Press; 2007:164–72.
   Google Scholar
• Nagasaka T, Gunji M, Hosokai N, et al. FISH 1p/19q deletion/imbalance for molecular subclassification of glioblastoma. Brain Tumor Pathol 2007;24:1–5.
   PubMed Web of Science ®Google Scholar
• Simon M, Boström JP, Hartmann C. Molecular genetics of meningiomas: from basic research to potential clinical applications. Neurosurgery 2007;60:787–98.
   PubMed Web of Science ®Google Scholar
• Scholzen T, Gerdes J. The Ki‐67 protein: from the known and the unknown. J Cell Physiol 2000;182:311–22.
   PubMed Web of Science ®Google Scholar
• Rezanko T, Akkalp AK, Tunakan M, Sari AA. MIB-1 counting methods in meningiomas and agreement among pathologists. Anal Quant Cytol Histol 2008;30:47–52.
   PubMed Web of Science ®Google Scholar
• Ho DM, Hsu CY, Ting LT, Chiang H. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma. Cancer 2002;94:1538–47.
   PubMed Web of Science ®Google Scholar
• Linsler S, Kraemer D, Driess C, et al. Molecular biological determinations of meningioma progression and recurrence. PLoS One 2014;9:e94987.
   Google Scholar
• Collins V. Brain tumours: classification and genes. J Neurol Neurosurg Psychiatry 2004;75:ii2–ii11.
   PubMed Web of Science ®Google Scholar
• Lamszus K. Meningioma pathology, genetics, and biology. J Neuropathol Exp Neurol 2004;63:275–86.
   PubMed Web of Science ®Google Scholar
• Pfisterer WK, Hank NC, Preul MC, et al. Diagnostic and prognostic significance of genetic regional heterogeneity in meningiomas. Neuro Oncol 2004;6:290–9.
   PubMed Web of Science ®Google Scholar
• Tabernero MD, Maíllo A, Nieto AB, et al. Delineation of commonly deleted chromosomal regions in meningiomas by high‐density single nucleotide polymorphism genotyping arrays. Genes Chromosomes Cancer 2012;51:606–17.
   PubMed Web of Science ®Google Scholar
• Nagasaka T, Gunji M, Hosokai N, et al. Fluorescent in situ hybridization 1p/19q deletion/imbalance analysis of low-grade and atypical meningiomas. Neuro Med-Chir 2010;50:27–32.
   PubMed Web of Science ®Google Scholar
• Ishino S, Hashimoto N, Fushiki S, et al. Loss of material from chromosome arm 1p during malignant progression of meningioma revealed by fluorescent in situ hybridization. Cancer 1998;83:360–6.
   PubMed Web of Science ®Google Scholar
• Simon M, von Deimling A, Larson JJ, et al. Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression. Cancer Res 1995;55:4696–701.
   PubMed Web of Science ®Google Scholar
• Alexiou GA, Markoula S, Gogou P, Kyritsis AP. Genetic and molecular alterations in meningiomas. Clin Neurol Neurosurg 2011;113:261–7.
   PubMed Web of Science ®Google Scholar
• Smith JS, Alderete B, Minn Y, et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 1999;18:4144–52.
   PubMed Web of Science ®Google Scholar
• Weller M, Berger H, Hartmann C, et al. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res 2007;13:6933–7.
   PubMed Web of Science ®Google Scholar
• Zhao J, Ma W, Zhao H. Loss of heterozygosity 1p/19q and survival in glioma: a meta-analysis. Neuro Oncol 2013;16:103–12.
   PubMed Web of Science ®Google Scholar
• Weber RG, Boström J, Wolter M, et al. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Nati Acad Sci USA 1997;94:14719–24.
   PubMed Web of Science ®Google Scholar
• Ozge O, SF I, Fatif A, Ozlem O, Zerrin Y, Nur A. Her-2/neu gene amplification in paraffin-embedded tissue sections of meningioma patients. Turk Neurosurg 2009;19:135–8.
   PubMed Web of Science ®Google Scholar
• Grimwood J, Gordon LA, Olsen A, et al. The DNA sequence and biology of human chromosome 19. Nature 2004;428:529–35.
   PubMed Web of Science ®Google Scholar
• Vogazianou AP, Chan R, Bäcklund LM, et al. Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses. Neuro-Oncol 2010;12:664–78.
   PubMed Web of Science ®Google Scholar
• Birnbaum DJ, Adélaïde J, Mamessier E, et al. Genome profiling of pancreatic adenocarcinoma. Genes Chromosomes Cancer 2011;50:456–65.
   PubMed Web of Science ®Google Scholar
• Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002;14:381–95.
   PubMed Web of Science ®Google Scholar
• Clark VE, Erson-Omay EZ, Serin A, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013;339:1077–80.
   PubMed Web of Science ®Google Scholar
• Brastianos PK, Horowitz PM, Santagata S, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 2013;45:285–9.
   PubMed Web of Science ®Google Scholar
• Yang P, Kollmeyer TM, Buckner K, Bamlet W, Ballman KV, Jenkins RB. Polymorphisms in GLTSCR1 and ERCC2 are associated with the development of oligodendrogliomas. Cancer 2005;103:2363–72.
   PubMed Web of Science ®Google Scholar
• Chaudhary K, Deb S, Moniaux N, Ponnusamy MP, Batra SK. Human RNA polymerase II-associated factor complex: dysregulation in cancer. Oncogene 2007;26:7499–507.
   PubMed Web of Science ®Google Scholar